Transoral Surgery + Reduced-Dose Radiation/Chemotherapy for Oropharyngeal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer. Giving reduced dose radiation therapy and chemotherapy after surgery may improve quality of life compared with standard of care primary chemoradiation approach without compromising survival.
Who Is on the Research Team?
Matin Imanguli, MD, DDS
Principal Investigator
Rutgers Cancer Institute of New Jersey
Are You a Good Fit for This Trial?
This trial is for adults with HPV-related throat cancer that can be surgically removed. Participants must have certain blood and organ function levels, not have had previous treatments for head and neck cancer, and women of childbearing age must test negative for pregnancy and use birth control. People with metastatic disease beyond the neck or serious health issues are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surgery
Participants undergo transoral surgery to remove the tumor
Adjuvant Therapy
Participants receive reduced dose radiation therapy and chemotherapy based on risk group
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cisplatin
- External Beam Radiation Therapy
- Transoral Surgery
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
National Cancer Institute (NCI)
Collaborator